Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1853-1857

  McCaffrey, J A ^a   Hilton, S ^a   Mazumdar, M ^a   Sadan, S ^a   Kelly, W K ^a   Scher, H I ^a   Bajorin, D F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; TRANSITIONAL CELL CARCINOMA;

EID: 0031005761     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1853     Document Type: Article

References (27)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics. CA Cancer J Clin 46:5-27, 1996
2. Sternberg CN, Scher HI: Current status of chemotherapy of the urothelial tract. Oncology 5:41-49, 1987
3. Yagoda A: Chemotherapy of metastatic bladder cancer. Cancer 45:1879-1888, 1980
4. Carter SK, Wasserman TH: The chemotherapy of urologic cancer. Cancer 36:729-747, 1975
5. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64:2448-2485, 1989
6. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study. J Clin Oncol 10:1066-1073, 1992
7. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
8. Wani MC, Taylor HL, Woll ME, et al: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327, 1971
9. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
10. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of taxotere (RPR56976, NSC628503) a taxol analogue. Cancer Res 51:4845-4852, 1991
11. Gardner MJ, Altman DG (eds): Statistics With Confidence. London, United Kingdom, BMJ, 1989
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
13. de Wit R, Stoter G, Blanc C, et al: Phase II study of firstline docetaxel (Taxotere) in patients with metastatic urothelial cancer. Ann Oncol 5:67, 1994 (suppl 8; abstr P331)
14. Roth BJ, Dreicer R, Einhorn LH: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994
15. Chevalier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
16. Hudis CA, Seidman AD, Crown JA, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
17. ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
18. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell cancer. J Clin Oncol 12:1238-1244, 1994
19. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
20. Catimel G, Verweij J, Mattijsen V, et al: Docetaxel: An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:533-537, 1994
21. Rougier P, De Forin M, Ademis A, et al: Phase II study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13:200, 1994 (abstr 587)
22. Sulkes A, Smyth J, Sessa C, et al: Docetaxel in advanced gastric carcinoma: Results of a phase II clinical trial. EORTC Early Clinical Trial Group. Br J Cancer 70:380-383, 1994
23. Bedikian AY, Weiss GR, Legha SS, et al: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma, previously untreated with chemotherapy. J Clin Oncol 13:2895-2899, 1995
24. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
25. Ravdin PM, Bums HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
26. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:422-428, 1996
27. Galindo E, Kavanagh J, Fossella F, et al: Docetaxel toxicities: An analysis of single institution experience in 168 patients (623 courses). Proc Am Soc Clin Oncol 14:164, 1994 (abstr 452)